Bristol-Myers Squibb Company
$60.58
+0.01 · +0.02% today
Market open · updated 12:18:50 PM ET
- High
- $61.98 4:05 AM
- Low
- $61.53 4:40 AM
Against the S&P 500 Price change through Oct 28, 2026
BMY+12.29%
S&P 500+13.26%
BMY+41.45%
S&P 500+12.41%
BMY+18.72%
S&P 500+88.06%
BMY+6.02%
S&P 500+68.51%
Key numbers
- Previous close
- $60.57
- Open
- $61.00
- Day's range
- $60.00 – $61.56
- 52-week range
- $43.20 – $68.64
- Volume
- 5.4 million
- Average volume
- 11.7 million
- Market value
- $123.7 billion
- Price to earnings
- 13.3last 12 months
- Earnings per share
- $4.55last 12 months
- Beta
- 0.23moves less than the market
- Dividend
- $2.52 a year · 4.16%
- 50-day average
- $62.98
- 200-day average
- $59.89
Thursday, Oct 29, 2026, before the open.
Analyst price targets and the full financials are in the terminal.
Who Bristol-Myers Squibb buys from and competes with From our value chain
Bristol-Myers Squibb in the news
- HeadlineBristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It MattersThe Motley Fool · October 27, 2026 at 2:13 AM ET
- HeadlineShould You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?Zacks Investment Research · October 26, 2026 at 3:36 PM ET
- HeadlineBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockMarketBeat · October 26, 2026 at 1:50 PM ET
- HeadlineBristol Myers Squibb: Bargain Buy or Value Trap?Fool - Investing News · October 26, 2026 at 1:08 PM ET
- HeadlineBristol Myers (BMY) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresZacks Investment Research · October 26, 2026 at 10:16 AM ET
- HeadlineIzalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 StudyBusiness Wire · October 26, 2026 at 3:30 AM ET
- Week aheadWeek Ahead: Fed Decision, GDP, PCE Inflation and Peak Earnings WeekWiseView Research desk · October 25, 2026
- HeadlineShould You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?The Motley Fool · October 25, 2026 at 5:15 PM ET
Earnings
Next report: Thursday, Oct 29, 2026, before the open.
Congress trades in BMY
2 purchases and 6 sales in the latest 8 filings.
| Member | Trade | Amount | Traded | Disclosed |
|---|---|---|---|---|
| Tommy TubervilleSenate · R-Alabama | Sale | $1,001 - $15,000 | Apr 15, 2025 | Aug 5, 2026 |
| Mike KellyHouse · R-Pennsylvania | Sale | $15,001 - $50,000 | May 7, 2026 | Jun 12, 2026 |
| Julie JohnsonHouse · D-Texas | Sale | $1,001 - $15,000 | Dec 18, 2025 | Jan 16, 2026 |
| Julia LetlowHouse · R-Louisiana | Sale | $1,001 - $15,000 | Apr 28, 2025 | Jan 14, 2026 |
| Gilbert CisnerosHouse · D-California | Purchase | $1,001 - $15,000 | Dec 19, 2025 | Jan 13, 2026 |
| Gilbert CisnerosHouse · D-California | Purchase | $1,001 - $15,000 | Nov 12, 2025 | Dec 16, 2025 |
| Julie JohnsonHouse · D-Texas | Sale | $1,001 - $15,000 | Nov 13, 2025 | Dec 12, 2025 |
| Gilbert CisnerosHouse · D-California | Sale | $1,001 - $15,000 | Oct 9, 2025 | Nov 19, 2025 |
Source: Periodic transaction reports filed with the House and the Senate · Members disclose ranges, not exact amounts, and may file weeks after the trade.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 32,500
- Headquarters
- Princeton, New Jersey
- Website
- bms.com
- Listed
- Jun 1, 1972
More drug manufacturers - general stocks
The price refreshes every 15 seconds while the market is open and carries the time it was read. Company figures are updated each evening. Built from WiseView and market data and public filings. For information only, not investment advice.